152 related articles for article (PubMed ID: 38195317)
21. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
Solomon BJ; Bauer TM; Mok TSK; Liu G; Mazieres J; de Marinis F; Goto Y; Kim DW; Wu YL; Jassem J; López FL; Soo RA; Shaw AT; Polli A; Messina R; Iadeluca L; Toffalorio F; Felip E
Lancet Respir Med; 2023 Apr; 11(4):354-366. PubMed ID: 36535300
[TBL] [Abstract][Full Text] [Related]
22. Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis.
Liu G; Lam VK
Adv Ther; 2023 Oct; 40(10):4117-4126. PubMed ID: 37573276
[TBL] [Abstract][Full Text] [Related]
23. Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK-positive non-small-cell lung cancer.
Goto Y; Shukuya T; Murata A; Kikkawa H; Emir B; Wiltshire R; Miura S
Cancer Sci; 2023 Jun; 114(6):2560-2568. PubMed ID: 36866958
[TBL] [Abstract][Full Text] [Related]
24. Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date.
Akamine T; Toyokawa G; Tagawa T; Seto T
Onco Targets Ther; 2018; 11():5093-5101. PubMed ID: 30174447
[TBL] [Abstract][Full Text] [Related]
25. Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC.
Ma X; Zhang K; Xu J; Gao H; Yang S; Qin H; Wang H; Gao F; Liu X
Thorac Cancer; 2023 Jul; 14(20):1980-1990. PubMed ID: 37265111
[TBL] [Abstract][Full Text] [Related]
26. Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
Leporati R; Miliziano D; Beninato T; Mazzeo L; Manglaviti S; Brambilla M; Occhipinti M; Prelaj A; Proto C; Lo Russo G
Tumori; 2024 Apr; ():3008916241246659. PubMed ID: 38623748
[TBL] [Abstract][Full Text] [Related]
27. An update on lorlatinib: a novel first line treatment for
Riudavets M; Planchard D
Expert Opin Pharmacother; 2023 Feb; 24(3):291-299. PubMed ID: 36542835
[TBL] [Abstract][Full Text] [Related]
28. Real world study of safety and efficacy of lorlatinib as second line and beyond in
Biswas B; Ghadyalpatil NS; Patil S; Patel A; Ganguly S; Rathore A; Guleria B; Tarannum CF; Ghosh J; Kondapally MS; Thippeswamy R; Reddy SHP; Roy S
Ecancermedicalscience; 2024; 18():1667. PubMed ID: 38439810
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Ma X; Yang S; Zhang K; Xu J; Lv P; Gao H; Qin H; Wang H; Liu X
Thorac Cancer; 2022 Jun; 13(12):1788-1794. PubMed ID: 35560808
[TBL] [Abstract][Full Text] [Related]
30. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT; Solomon BJ; Chiari R; Riely GJ; Besse B; Soo RA; Kao S; Lin CC; Bauer TM; Clancy JS; Thurm H; Martini JF; Peltz G; Abbattista A; Li S; Ou SI
Lancet Oncol; 2019 Dec; 20(12):1691-1701. PubMed ID: 31669155
[TBL] [Abstract][Full Text] [Related]
31. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With
Goto Y; Kenmotsu H; Tamiya M; Murakami S; Kurata T; Yanagitani N; Taniguchi H; Kuyama S; Shimizu J; Yokoyama T; Shimada N; Maeda T; Tamiya A; Uchiyama A; Imaizumi K; Takahama T; Kato T; Hayashi H; Shiraiwa N; Toyoizumi S; Kikkawa H; Thomaidou D; Nishio M
JTO Clin Res Rep; 2023 May; 4(5):100508. PubMed ID: 37250506
[TBL] [Abstract][Full Text] [Related]
32. Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer.
Lu S; Zhou Q; Liu X; Du Y; Fan Y; Cheng Y; He S; Zhao H; Li H; Wu YL
Clin Lung Cancer; 2024 Apr; ():. PubMed ID: 38879393
[TBL] [Abstract][Full Text] [Related]
33. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
34. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
Girard N; Galland-Girodet S; Avrillon V; Besse B; Duruisseaux M; Cadranel J; Otto J; Prevost A; Roch B; Bennouna J; Bouledrak K; Coudurier M; Egenod T; Lamy R; Ricordel C; Moro-Sibilot D; Odier L; Tillon-Strozyk J; Zalcman G; Missy P; Westeel V; Baldacci S
ESMO Open; 2022 Apr; 7(2):100418. PubMed ID: 35227966
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece.
Gourzoulidis G; Zisimopoulou O; Boubouchairopoulou N; Michailidi C; Lowry C; Tzanetakos C; Kourlaba G
J Health Econ Outcomes Res; 2022; 9(1):50-57. PubMed ID: 35620456
[No Abstract] [Full Text] [Related]
36. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
Dagogo-Jack I; Oxnard GR; Evangelist M; Digumarthy SR; Lin JJ; Gainor JF; Murphy JF; Rabin MS; Heist RS; Muzikansky A; Shaw AT
JCO Precis Oncol; 2022 May; 6():e2100522. PubMed ID: 35584349
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive clinical evaluation of first-line drugs for ALK-positive advanced non-small cell lung cancer.
Wang WQ; Xu T; Zhang JJ; Wang Y; Wang Y; Zhang W; Zhu JG
J Thorac Dis; 2023 Apr; 15(4):1935-1947. PubMed ID: 37197536
[TBL] [Abstract][Full Text] [Related]
38. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
Ou SI; Lee ATM; Nagasaka M
Crit Rev Oncol Hematol; 2023 Jul; 187():104019. PubMed ID: 37187318
[TBL] [Abstract][Full Text] [Related]
39. Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
Schmid S; Cheng S; Chotai S; Garcia M; Zhan L; Hueniken K; Balaratnam K; Khan K; Patel D; Grant B; Raptis R; Brown MC; Xu W; Moriarty P; Shepherd FA; Sacher AG; Leighl NB; Bradbury PA; Liu G
Clin Lung Cancer; 2023 Jan; 24(1):40-50. PubMed ID: 36270866
[TBL] [Abstract][Full Text] [Related]
40. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
Ou SI; Solomon BJ; Shaw AT; Gadgeel SM; Besse B; Soo RA; Abbattista A; Toffalorio F; Wiltshire R; Bearz A
J Thorac Oncol; 2022 Apr; 17(4):568-577. PubMed ID: 35026476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
